The EGAPP Working Group was established in 2005 to support the development of a systematic process for assessing the available evidence regarding the validity and utility of rapidly emerging genetic tests for clinical practice. This independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-commissioned evidence reports and other contextual factors, highlights critical knowledge gaps, and provides guidance on appropriate use of genetic tests in specific clinical scenarios.
Nominations for EGAPP Working Group membership are accepted on a continuous basis.
The EGAPP Working Group has published a new article entitled “Description and pilot results from a novel method for evaluating return of incidental findings from next-generation sequencing technologies” (PDF 656KB) in collaboration with Kaiser Permanente Center for Health Research.
File Format Help:
Page last updated: May 20, 2013
Page last reviewed: April 10, 2013
Content Source: OPHG Staff